Skip to content
Adrienne Monson – Lifestyle
Author:
PridCor Therapeutics, LLC
PridCor Therapeutics Advances Phase 2 SHIELD Study of a Combination Antiviral Regimen for Long COVID Toward Enrollment
September 24, 2026
PridCor Therapeutics Secures Global Antiviral Portfolio, Establishing Leadership in Treatment of Long COVID and Infection-Associated Chronic Illnesses
April 23, 2026